PER 0.00% 10.0¢ percheron therapeutics limited

should buy now, page-18

  1. 2,843 Posts.

    Given the success of ATL1103 suppressing circulating levels of IGF-I in primates and toxicology well in the range of being able to continue to the human trials, i would suggest that these human trials will be a success given the close physiology of Humans and Primates and given ISIS is closely monitoring these studies and their close working relationship with ANP.Potentially a real breakthrough in modern medicine.
    Robbbssstttaarrr
 
watchlist Created with Sketch. Add PER (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.